

Allergan plc  
Form 8-K  
February 03, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): February 3, 2017 (February 1, 2017)**

**ALLERGAN PLC**

**(Exact Name of Registrant as Specified in Charter)**

**Ireland**  
**(State or Other Jurisdiction**

**of Incorporation)**

**001-36867**  
**(Commission**

**File Number)**  
**Clonshaugh Business and Technology Park**

**98-1114402**  
**(IRS Employer**

**Identification No.)**

Edgar Filing: Allergan plc - Form 8-K

**Coolock, Dublin, D17 E400, Ireland**

**(Address of Principal Executive Offices)**

**(862) 261-7000**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On February 1, 2017, the Board of Directors (the Board) of Allergan plc (the Company) elected Ms. Adriane M. Brown as a director of the Company, effective immediately. Ms. Brown's appointment to the Board was previously announced by the Company in November 2016. Ms. Brown has been named to the Quality and Innovation Committee of the Board.

On February 1, 2017, Mr. Michael R. Gallagher announced he would not stand for reelection to the Board at the Company's Annual General Meeting of Shareholders (AGM) on May 4, 2017.

**Item 8.01 Other Events.**

On February 2, 2017, the Board set a record date of March 8, 2017 for participation in the Company's 2017 AGM. Only those shareholders of the Company who are shareholders of record at the close of business on March 8, 2017 will be entitled to receive notice of, and to vote, at the 2017 AGM. The Board also announced that the Company's 2017 AGM would be held on May 4, 2017.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 3, 2017

Allergan plc

By: /s/ A. Robert D. Bailey  
A. Robert D. Bailey  
EVP, Chief Legal Officer and Corporate Secretary